Skip to main content
ALEMBIC PHARMACEUTICALS LIMITED logo

ALEMBIC PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · APLLTD ISIN · INE901L01018 LEI · 335800PM173KNG818V30 BSE.NS Manufacturing
Open in API
Filings indexed 1,367 across all filing types
Latest filing 2026-05-15 Earnings Release
Country IN India
Listing BSE.NS APLLTD

About ALEMBIC PHARMACEUTICALS LIMITED

https://www.alembicpharmaceuticals.com

Alembic Pharmaceuticals Limited is a vertically integrated pharmaceutical organization engaged in the development, manufacturing, and marketing of generic pharmaceutical products, active pharmaceutical ingredients (APIs), and formulations. Established in 1907, the company operates advanced research and development centers and manufacturing facilities that adhere to international regulatory standards, including USFDA compliance. Its diverse product portfolio covers key therapeutic areas such as anti-infectives, cardiology, gynecology, gastrointestinal, and dermatology. Alembic maintains a strong global presence, supplying high-quality medications to markets in North America, Europe, and various emerging regions. The company prioritizes innovation through its focus on complex generics and specialty products, aiming to provide affordable and effective healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Please find attached.
Earnings Release Classification · 90% confidence The document is a press release addressed to stock exchanges announcing the audited financial results for the quarter and full year ended March 31, 2026. It provides headline financial metrics (revenue, net profit, EBITDA), operational highlights, and earnings call details. It does not contain full financial statements or a management discussion and analysis but instead is the initial public announcement of quarterly results, which matches the definition of an Earnings Release (ER). FY 2026
2026-05-15 English
Press Release
Earnings Release Classification · 90% confidence The document is a press release submitted to stock exchanges summarizing key financial results (revenue, profit, EBITDA, segment performance) for Q4 FY26 and FY26. It provides headline figures and commentary, rather than full financial statements, fitting the definition of an Earnings Release. FY 2026
2026-05-15 English
Please find attached.
Investor Presentation Classification · 95% confidence The document is an official letter to stock exchanges enclosing the Investor Presentation on Audited Financial Results for the quarter and FY ended 31 March 2026. It contains slide decks with financial highlights, quarterly/annual snapshots, business segment analysis, ESG targets, and company overview. This is clearly a detailed investor presentation rather than a regulatory notice or the full annual report itself.
2026-05-15 English
Please fin enclosed herewith Audited Financial Results for the quarter and Financial Year ended 31st March, 2026.
Earnings Release Classification · 88% confidence The document is an official stock‐exchange filing under SEBI Regulation 33 describing the “Outcome of Board Meeting” held on 15 May 2026. It provides the audited standalone and consolidated financial results for the quarter and financial year ended 31 March 2026, including statements of profit and loss, assets and liabilities, cash flows, detailed notes, and a dividend recommendation. This is the initial announcement of the company’s periodical financial results rather than a full annual report or memorandum. Therefore, it best fits the Earnings Release category. FY 2026
2026-05-15 English
Investor Presentation
Investor Presentation Classification · 94% confidence The document is titled “Investor Presentation on Audited Financial Results… for the quarter and financial year ended 31st March, 2026” and contains slide‐style content: Safe Harbour statement, quarterly snapshots, segment revenue tables and charts, full P&L detail, business‐unit performance, ESG and company overview slides. It is a detailed presentation rather than a brief earnings release or regulatory notice. Therefore, it should be classified as an Investor Presentation (IP).
2026-05-15 English
Outcome of Board Meeting
Regulatory Filings
2026-05-15 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.